Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Arthralgia, Body temperature, Lymphadenopathy, Pyrexia, SARS-CoV-2 test
Clinical narrative: moderate soreness at injection site; swelling and soreness of infraclavicular lymph node; lowgrade fever (101); joint aching; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 22Apr2023 as dose 6 (booster), single (Lot number: GL0087) at the age of 72 years for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: BNT162b2 (Dose: 01, Lot: EL9262), administration date: 28Jan2021, when the patient was 69-year-old, for COVID-19 immunization, reaction(s): "moderate soreness at injection site", "swelling and soreness of infraclavicular lymph node"; BNT162b2 (Dose: 02, Lot: EN6200), administration date: 17Feb2021, when the patient was 70-year-old, for COVID-19 immunization, reaction(s): "moderate soreness at injection site", "swelling and soreness of infraclavicular lymph node"; BNT162b2 (Dose: 03, Lot: FC3181), administration date: 21Aug2021, when the patient was 70-year-old, for COVID-19 immunization, reaction(s): "moderate soreness at injection site", "swelling and soreness of infraclavicular lymph node"; coviD-19 vaccine moderna (Dose: 04, Lot: 002M21A), administration date: 04Apr2022, when the patient was 71-year-old, for COVID-19 immunization, reaction(s): "moderate soreness at injection site", "swelling and soreness of infraclavicular lymph node", "Dose: 4 Moderna, Dose: 5 Pfizer"; BNT162b2;BNT162b2 omi ba.4-5 (Dose: 05, Lot: GH9694), administration date: 09Sep2022, when the patient was 71-year-old, for COVID-19 immunization, reaction(s): "moderate soreness at injection site", "swelling and soreness of infraclavicular lymph node". The following information was reported: ARTHRALGIA (non-serious) with onset Apr2023, 24 hrs after the suspect product(s) administration, outcome "recovered" (2023), described as "joint aching"; PYREXIA (non-serious) with onset Apr2023, 24 hrs after the suspect product(s) administration, outcome "recovered" (2023), described as "lowgrade fever (101)"; VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "moderate soreness at injection site"; LYMPHADENOPATHY (non-serious), outcome "unknown", described as "swelling and soreness of infraclavicular lymph node". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of pyrexia, arthralgia.  Additional information: Prior Vaccinations: None. Family Medical History Relevant to Adverse Events (AES): No one in family has had adverse reaction to vaccines of any kind. Relevant Tests and Specific Relevant Test for Thromboembolic Events with Thrombocytopenia: None. It was reported that this was 6th COVID vaccine of patient. All previous where Pfizer expect 5 which was Merck (as reported). Moderate soreness at injection site swelling and soreness of infraclavicular lymph node experienced with each of the COVID infections. Last injection 22Apr2023 was followed 24 hours later with low grade fever 101, joint aching which resolved w/o TX. The Product did not work as expected. Contracted positive COVID 3 weeks past vaccine Checked. The patient experienced adverse event(s) due to the lack of effect of the product. Patient tested positive for COVID 17May2023 (photo of home test enclosed) Tx w/paxlovid patient experienced fever, lethargy, aching for 24 hours. Then symptoms resolved negative COVID, home test 22May2023.